MATINAS BIOPHARMA HOLDINGS, INC. Available-for-sale Securities, Gross Unrealized Gain
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Available-for-sale Securities, Gross Unrealized Gain of $61.00 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2021-08-10
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2021-06-30 was -$78.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2021-03-31 was $139.00K, a 26077.02% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2020-12-31 was $227.63K.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2020-09-30 was -$114.00.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month |
|---|---|---|---|---|
| 2021-06-30 | -$78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $61.00K 10-Q · filed 2021-08-10 | $288.63K derived: sum of 3 quarters · filed 2021-08-10 | $288.52K derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | $139.00K 10-Q · filed 2021-05-10 | $366.63K derived: sum of 2 quarters · filed 2021-08-10 | $366.52K derived: sum of 3 quarters · filed 2021-08-10 | $366.47K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-12-31 | $227.63K derived: 10-Q 12 month − 10-Q 9 month · filed 2021-08-10 | $227.52K derived: sum of 2 quarters · filed 2021-08-10 | $227.47K derived: sum of 3 quarters · filed 2021-08-10 | $228.00K 10-Q · filed 2021-08-10 |
| 2020-09-30 | -$114.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$166.00 derived: sum of 2 quarters · filed 2020-11-06 | $365.00 10-Q · filed 2020-11-06 | |
| 2020-06-30 | -$52.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $479.00 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | $531.00 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |